Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. - Wikidata - wikimedia - TriplyDB

Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.

Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.

http://www.wikidata.org/entity/Q38502298

about

PET/CT imaging of Mycobacterium tuberculosis infection A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People.Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies.Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis.Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.Nonclinical models for antituberculosis drug development: a landscape analysis.Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis.Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting.Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis Taxa-function robustness in microbial communities.Linking minimum inhibitory concentrations to whole genome sequence-predicted drug resistance in Mycobacterium tuberculosis strains from Romania.The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes

P2860

Q26748493-DD08975B-C276-4174-A817-F91E5D7C54E7 Q30275728-4E1B0AF5-772A-4FCB-BECD-9EBDD0A936B4 Q30395441-D6AFABF2-DB96-45BD-8851-EB2C05DE0B14 Q36075986-7CACA0D5-C4D5-4981-959D-26D8B0BBD0AA Q36242447-67481BD6-4363-4A2C-9251-F9E1D9FA8BA8 Q36540893-8F9C7AA6-F759-44CB-A2A6-F4D2A498789E Q36644647-077C211F-255F-40B8-B693-F45AFE7DBAF9 Q36730088-F952F2A0-D27B-4C64-AAB5-633148376D80 Q36887811-C0C21E82-2664-41B7-83EE-5B9C4CE98ED7 Q36933441-18B19177-6F53-4660-A8DA-558153E039E7 Q37120152-3267C818-F51E-48DB-8FD1-E01F59366BF3 Q37287830-A4B53AC6-8D5D-4CB3-9012-1EF171CE3C54 Q37339287-47AB20DA-D294-4763-B3C4-E74CDE8590D2 Q37339290-E618FF9F-B0B1-408E-BA4D-DA30DE4FCEC6 Q37339294-B739274D-7BE4-4BE0-87AF-DA69BCF07606 Q38502294-700A49F9-50C7-46AC-81A5-E8C21241C927 Q38763608-0CEC6FD3-AE9F-494F-8F8B-EBCE96F23912 Q38979626-05F704ED-0E76-4CF6-856F-EF602C0C4935 Q40065397-A7D44F1C-8A9C-4F85-82B5-DBBC5A2A8F1D Q40139991-2DB66E8D-7860-43F5-B8D1-E2AA70F2546A Q40184248-0E04E9E0-2DF4-4F32-B2EF-3FE4CA558AEA Q40679730-932B34F8-6617-4151-A1A5-9EF435DD965F Q41082086-6409F2DE-83D9-43EC-AAA9-9F7797A798AD Q41996871-98AC2339-5D79-400A-A2C2-C23F6B8B7683 Q42263053-C8F1ECB8-6B3A-4F5C-B01B-5F2CA88AF205 Q52676704-E6789A09-6424-4B65-A026-C52BA980B952 Q55424405-9B3E269B-2D21-4314-A5D7-047D250B8527 Q57152709-2AA3CC09-F406-4A02-A0F1-EA712BDD2DCB

P2860

Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.

http://www.wikidata.org/entity/Q38502298

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Pharmacokinetic-pharmacodynami ...... rds for industry and academia.

@en

type

label

Pharmacokinetic-pharmacodynami ...... rds for industry and academia.

@en

prefLabel

Pharmacokinetic-pharmacodynami ...... rds for industry and academia.

@en

P1433

Q38502298-7B5CC7C9-5861-44DD-BD32-FAE3427295DE

P1476

Q38502298-49B03CE7-3B19-44F4-A2A8-03D4E6DDC831

P2093

Q38502298-63F34182-BEB7-4BC0-BEDD-900297FB6CE9

Q38502298-F8F2DABC-1E9F-42F3-8428-C570BEAF6B99

P2860

Q38502298-01691AD7-B8B9-4BCE-A1D3-4C5CA64C4FFA

Q38502298-0ACFC867-6EFC-47F4-B74F-D9CF56023E85

Q38502298-0CEB56E3-8485-4AE9-AD1D-C49336A815F0

Q38502298-0D311B16-890B-41B0-BF99-5A0A612439D0

Q38502298-10C0BB39-7376-480A-A60B-2890CF80B38F

Q38502298-17539704-11C4-498E-B267-C76900F1969C

Q38502298-193E5319-2E13-4552-8CC8-51D6B6D82883

Q38502298-1AC2E78D-D515-4471-AD76-696EB7D03CC7

Q38502298-1C631BB7-814D-4146-AECA-5CE63C064377

Q38502298-2B0FDFEA-35BF-4F43-9F08-EE6E1BB3B9D8

P304

Q38502298-CA93D985-0810-4564-A3E7-4BF97700D276

P31

Q38502298-7756BDD0-F8E6-4E5F-8920-9D5DB35B91A7

P356

Q38502298-4C14B312-82DD-44FD-8E86-AEA2A248E1F5

P407

Q38502298-47506611-4ADE-4027-A946-C553A08EF1F7

P478

Q38502298-9B6AC856-A3BB-4937-8174-53D3D6005F24

P50

Q38502298-01DAF8D3-DA82-4CA2-8E2A-E1FA3306EBF0

P577

Q38502298-5AE1EDAD-9F5C-43DF-AED2-3D22AE83A88B

P698

Q38502298-6F4CD1E4-042D-446A-B651-DFDDEA467DC8

P356

P1433

The Journal of Infectious Diseases

P1476

Pharmacokinetic-pharmacodynami ...... rds for industry and academia.

@en

P2093

Iñigo Angulo-Barturen

http://www.w3.org/2001/XMLSchema#string

Santiago Ferrer-Bazaga

http://www.w3.org/2001/XMLSchema#string

P2860

Approval of a Tuberculosis Drug Based on a Paradoxical Surrogate Measure

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility results

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

The triple combination indinavir-zidovudine-lamivudine is highly synergistic.

The pyrazinamide susceptibility breakpoint above which combination therapy fails.

Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients

Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model

Re-evaluation of the critical concentration for ethambutol antimicrobial sensitivity testing on the MGIT 960.

P304

S96-S106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIU610

http://www.w3.org/2001/XMLSchema#string

P407

P478

211 Suppl 3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26009618

http://www.w3.org/2001/XMLSchema#string